T

Teyi Pharmaceutical Group Co Ltd
SZSE:002728

Watchlist Manager
Teyi Pharmaceutical Group Co Ltd
SZSE:002728
Watchlist
Price: 9.27 CNY -1.38% Market Closed
Market Cap: 4.7B CNY
Have any thoughts about
Teyi Pharmaceutical Group Co Ltd?
Write Note

Teyi Pharmaceutical Group Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Teyi Pharmaceutical Group Co Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
T
Teyi Pharmaceutical Group Co Ltd
SZSE:002728
Cost of Revenue
-ÂĄ440.7m
CAGR 3-Years
-7%
CAGR 5-Years
-3%
CAGR 10-Years
-8%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cost of Revenue
-ÂĄ1B
CAGR 3-Years
-9%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cost of Revenue
-ÂĄ6.1B
CAGR 3-Years
-17%
CAGR 5-Years
-14%
CAGR 10-Years
-24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cost of Revenue
-ÂĄ3.9B
CAGR 3-Years
0%
CAGR 5-Years
-5%
CAGR 10-Years
-11%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cost of Revenue
-ÂĄ28.8B
CAGR 3-Years
-2%
CAGR 5-Years
-7%
CAGR 10-Years
-9%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cost of Revenue
-ÂĄ242.3m
CAGR 3-Years
-6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Teyi Pharmaceutical Group Co Ltd
Glance View

Market Cap
4.7B CNY
Industry
Pharmaceuticals

Teyi Pharmaceutical Group Co., Ltd. engages in the pharmaceutical manufacturing and pharmaceutical health industry. The company is headquartered in Jiangmen, Guangdong and currently employs 1,200 full-time employees. The company went IPO on 2014-07-31. The firm primarily provides Chinese traditional patent medicines, including cough arresting and phlegm removing medicine series, kidney reinforcing medicine series and anti-infection medicine series, among others. The firm's products mainly include tablets, granules, medicinal tea, syrup, decocted extracts, capsules, powder, ointment, cream, as well as oral solutions, among others.

Intrinsic Value
11.66 CNY
Undervaluation 21%
Intrinsic Value
Price
T

See Also

What is Teyi Pharmaceutical Group Co Ltd's Cost of Revenue?
Cost of Revenue
-440.7m CNY

Based on the financial report for Sep 30, 2024, Teyi Pharmaceutical Group Co Ltd's Cost of Revenue amounts to -440.7m CNY.

What is Teyi Pharmaceutical Group Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-8%

Over the last year, the Cost of Revenue growth was 7%. The average annual Cost of Revenue growth rates for Teyi Pharmaceutical Group Co Ltd have been -7% over the past three years , -3% over the past five years , and -8% over the past ten years .

Back to Top